NCT03685331View on ClinicalTrials.gov

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients with BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 15, 2020

Primary Completion Date

August 1, 2025

Study Completion Date

August 31, 2025

Conditions

Metastatic Breast CancerLocally Advanced Breast CancerAdvanced Breast CancerBRCA2 MutationBRCA1 Mutation

Interventions

DRUG

Palbociclib

Combination of palbociclib, olaparib, and fulvestrant.

DRUG

Olaparib

Combination of palbociclib, olaparib, and fulvestrant.

DRUG

Fulvestrant

Combination of palbociclib, olaparib, and fulvestrant.

Trial Locations (1)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors

lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT03685331 - HOPE: Olaparib, Palbociclib and Fulvestrant in Patients with BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer | Biotech Hunter | Biotech Hunter